Your browser doesn't support javascript.
loading
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter, Bing Z; Mak, Po Yee; Tao, Wenjing; Ayoub, Edward; Ostermann, Lauren B; Huang, Xuelin; Loghavi, Sanam; Boettcher, Steffen; Nishida, Yuki; Ruvolo, Vivian; Hughes, Paul E; Morrow, Phuong K; Haferlach, Torsten; Kornblau, Steven; Muftuoglu, Muharrem; Andreeff, Michael.
  • Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bicarter@mdanderson.org.
  • Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ayoub E; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Boettcher S; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Nishida Y; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ruvolo V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hughes PE; Oncology Research, Amgen Inc, Thousand Oaks, CA, USA.
  • Morrow PK; Amgen Inc, Thousand Oaks, CA, USA.
  • Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Kornblau S; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Muftuoglu M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.
Blood Cancer J ; 13(1): 80, 2023 May 17.
Article en En | MEDLINE | ID: mdl-37193700
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article